Human normal immunoglobulin in Portugal: Analysing price increases across multiple markets

Ana Correia, Claudia Furtado, Sonia Caldeira (National Authority of Medicines and Health Products (INFARMED, I.P.))

In Portugal, the price developments of medicines containing HNIg and HA were different. An increase in the price of HNIg was observed in Portugal, notably in 2021, while no price variation occurred with HA. When compared to other European countries, there is a trend of increase in both medicines, although the increase in HA is more recent and more pronounced in 2023.

Despite the increase observed in HNIg, Portugal continues to present a cost per mg below the average of the other countries. Regarding HA, it has the lowest cost.

Given the behaviour observed in other countries, it is expected that there will also be an increase in the cost of HA in Portugal in the upcoming years.

The EURIPID collaboration is currently funded by an annual contribution fee of the participants and – for defined tasks and deliverables – a grant of the EU.

This website is part of the project ’826652 Euripid’ which is co-funded by the European Union’s Health Programme (2014-2020).

The content of this website represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.

Human normal immunoglobulin in Portugal: Analysing price increases across multiple markets

Collaborating Across Europe to Ensure Fair, Accessible, and Sustainable Healthcare

© Copyright – EURIPID